A5069894827- Alzheimer's disease research and treatments
- Dementia and Cognitive Impairment Research
- Neuroinflammation and Neurodegeneration Mechanisms
- Functional Brain Connectivity Studies
- Advanced Neuroimaging Techniques and Applications
- Neurological Disease Mechanisms and Treatments
- Congenital Heart Disease Studies
- Medical Imaging Techniques and Applications
- Advanced MRI Techniques and Applications
- Cardiac Valve Diseases and Treatments
- Cardiovascular Function and Risk Factors
- Mechanical Circulatory Support Devices
- Tryptophan and brain disorders
- Cardiac Structural Anomalies and Repair
- S100 Proteins and Annexins
- Hemodynamic Monitoring and Therapy
- Ultrasound in Clinical Applications
- Neuroscience and Neuropharmacology Research
- Health, Environment, Cognitive Aging
- Infective Endocarditis Diagnosis and Management
- Cardiac Arrhythmias and Treatments
- Cardiovascular Conditions and Treatments
- Pericarditis and Cardiac Tamponade
- Lanthanide and Transition Metal Complexes
- Bipolar Disorder and Treatment
McGill University
2019-2025
Montreal Neurological Institute and Hospital
2019-2025
McGill University Health Centre
2019-2025
Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal
2020-2025
Centre Intégré Universitaire de Santé et de Services Sociaux du Saguenay–Lac-Saint-Jean
2020-2025
Lawrence Berkeley National Laboratory
2024-2025
Douglas Mental Health University Institute
2019-2025
University of Pittsburgh
2021-2025
Amazentis (Switzerland)
2023-2025
École Polytechnique Fédérale de Lausanne
2023-2025
Glial fibrillary acidic protein (GFAP) is a marker of reactive astrogliosis that increases in the cerebrospinal fluid (CSF) and blood individuals with Alzheimer disease (AD). However, it not known whether there are differences GFAP levels across entire AD continuum its performance similar to CSF GFAP.To evaluate plasma throughout continuum, from preclinical dementia, compared GFAP.This observational, cross-sectional study collected data July 29, 2014, January 31, 2020, 3 centers. The...
Importance Phosphorylated tau (p-tau) is a specific blood biomarker for Alzheimer disease (AD) pathology, with p-tau217 considered to have the most utility. However, availability of tests research and clinical use has been limited. Expanding access this highly accurate AD crucial wider evaluation implementation tests. Objective To determine utility novel commercially available immunoassay plasma detect pathology evaluate reference ranges abnormal amyloid β (Aβ) longitudinal change across 3...
Braak stages of tau neurofibrillary tangle accumulation have been incorporated in the criteria for neuropathological diagnosis Alzheimer's disease. It is expected that staging using brain imaging can stratify living individuals according to their individual patterns deposition, which may prove crucial clinical trials and practice. However, previous studies first-generation PET agents shown a low sensitivity detect pathology areas corresponding early histopathological (∼20% cognitively...
<h3>Importance</h3> Apolipoprotein E ε4 (<i>APOEε4</i>) is the single most important genetic risk factor for Alzheimer disease. While<i>APOEε4</i>is associated with increased amyloid-β burden, its association cerebral tau pathology has been controversial. <h3>Objective</h3> To determine whether<i>APOEε4</i>is medial temporal independently of amyloid-β, sex, clinical status, and age. <h3>Design, Setting, Participants</h3> This a study 2 cross-sectional cohorts volunteers who were cognitively...
Abstract An unresolved question for the understanding of Alzheimer’s disease (AD) pathophysiology is why a significant percentage amyloid-β (Aβ)-positive cognitively unimpaired (CU) individuals do not develop detectable downstream tau pathology and, consequently, clinical deterioration. In vitro evidence suggests that reactive astrocytes unleash Aβ effects in pathological phosphorylation. Here, biomarker study across three cohorts ( n = 1,016), we tested whether astrocyte reactivity...
Abstract Gold-standard diagnosis of Alzheimer’s disease (AD) relies on histopathological staging systems. Using the topographical information from [ 18 F]MK6240 tau positron-emission tomography (PET), we applied Braak system to 324 living individuals. We used PET-based stage model trajectories amyloid-β, phosphorylated (pTau) in cerebrospinal fluid (pTau 181 , pTau 217 231 and 235 ) plasma ), neurodegeneration cognitive symptoms. identified nonlinear AD biomarker corresponding spatial extent...
Importance The recent proliferation of phosphorylated tau (p-tau) biomarkers has raised questions about their preferential association with the hallmark pathologies Alzheimer disease (AD): amyloid-β plaques and neurofibrillary tangles. Objective To determine whether cerebrospinal fluid (CSF) plasma p-tau preferentially reflect cerebral β-amyloidosis or tangle aggregation measured positron emission tomography (PET). Design, Setting, Participants This was a cross-sectional study 2...
Cost-effective strategies for identifying amyloid-β (Aβ) positivity in patients with cognitive impairment are urgently needed recent approvals of anti-Aβ immunotherapies Alzheimer's disease (AD). Blood biomarkers can accurately detect AD pathology, but it is unclear whether their incorporation into a full diagnostic workflow reduce the number confirmatory cerebrospinal fluid (CSF) or positron emission tomography (PET) tests while classifying patients. We evaluated two-step determining Aβ-PET...
Astrocytes can adopt multiple molecular phenotypes in the brain of Alzheimer's disease (AD) patients. Here, we studied associations cerebrospinal fluid (CSF) glial fibrillary acidic protein (GFAP) and chitinase-3-like 1 (YKL-40) levels with amyloid-β (Aβ) tau pathologies. We assessed 121 individuals across aging AD clinical spectrum positron emission tomography (PET) imaging for Aβ ([
Abstract INTRODUCTION Plasma biomarkers are promising tools for Alzheimer's disease (AD) diagnosis, but comparisons with more established needed. METHODS We assessed the diagnostic performance of p‐tau 181 , 217 and 231 in plasma CSF 174 individuals evaluated by dementia specialists amyloid‐PET tau‐PET. Receiver operating characteristic (ROC) analyses to identify tau‐PET positivity. RESULTS had lower dynamic ranges effect sizes compared p‐tau. (AUC = 76%) 82%) assessments performed inferior...
Abstract Blood phosphorylated tau (p-tau) biomarkers, at differing sites, demonstrate high accuracy to detect Alzheimerʼs disease (AD). However, knowledge on the optimal marker for identification across AD continuum and link pathology is limited. This partly due heterogeneity in analytical methods. In this study, we employed an immunoprecipitation mass spectrometry method simultaneously quantify six (p-tau181, p-tau199, p-tau202, p-tau205, p-tau217 p-tau231) two non-phosphorylated plasma...
Animal studies suggest that the apolipoprotein E ε4 (
Patients with Alzheimer's disease (AD) little or no quantifiable insoluble brain tau neurofibrillary tangle (NFT) pathology demonstrate stronger clinical benefits of therapies than those advanced NFTs. The formation NFTs can be prevented by targeting the intermediate soluble assemblies (STAs). However, biochemical understanding and biomarkers STAs are lacking. We show that Tris-buffered saline-soluble aggregates from autopsy-verified AD tissues include core sequence ~tau258-368. In...
Recommendations for neonatologist performed echocardiography in Europe: Consensus Statement endorsed by European Society Paediatric Research (ESPR) and Neonatology (ESN)
Abstract Introduction Mild behavioral impairment (MBI) is characterized by the emergence of neuropsychiatric symptoms in elderly persons. Here, we examine associations between MBI and Alzheimer's disease (AD) biomarkers asymptomatic individuals. Methods Ninety‐six cognitively normal individuals underwent MRI, [ 18 F]AZD4694 β‐amyloid‐PET, F]MK6240 tau‐PET. was assessed using Checklist (MBI‐C). Pearson's correlations voxel‐based regressions were used to evaluate relationship MBI‐C score...
Amyloid-β deposition into plaques is a pathologic hallmark of Alzheimer disease appearing years before the onset symptoms. Although cerebral amyloid-β occurs on continuum, dichotomization positive and negative groups has advantages for diagnosis, clinical management, population enrichment trials. <sup>18</sup>F-AZD4694 (also known as <sup>18</sup>F-NAV4694) an imaging ligand with high affinity plaques. Despite being used in multiple academic centers, no studies have assessed quantitative...
Tracking longitudinal tau tangles accumulation across the Alzheimer's disease continuum is crucial to better understand natural history of pathology and for clinical trials. Although available first-generation PET tracers detect in symptomatic individuals, their nanomolar affinity offers limited sensitivity early asymptomatic subjects. Here, we hypothesized novel subnanomolar tracer 18F-MK-6240 can We studied 125 living individuals (65 cognitively unimpaired elderly amyloid-β-negative, 22...
APOEε4 is the most well-established genetic risk factor for sporadic Alzheimer's disease and associated with cerebral amyloid-β. However, association between tau pathology, other major proteinopathy of disease, has been controversial. Here, we sought to determine whether relationship pathology determined by local interactions We examined three independent samples cognitively unimpaired, mild cognitive impairment subjects: (1) 211 participants who underwent tau-PET [18F]MK6240 amyloid-PET...
Objectives To explore whether regional tau binding measured at baseline is associated with the rapidity of Alzheimer’s disease (AD) progression over 2 years, as assessed by decline in specified cognitive domains, and brain atrophy, comparison amyloid-positron emission tomography (PET), MRI cerebrospinal fluid (CSF) biomarkers. Methods Thirty-six patients AD (positive CSF biomarkers amyloid-PET) 15 controls underwent a complete neuropsychological assessment, 3T MRI, [ 11 C]-PiB 18...